Jinghua Pharmaceutical (002349.SZ): Jidesheng Snake Medicine Tablets receives drug clinical trial approval for new indication of herpes zoster

Zhitong Finance APP News, Jinghua Pharmaceutical (002349.SZ) issued an announcement. Recently, the company received the "Drug Clinical Trial Approval Notice" (Acceptance Number: CXZL2600062; Notice Number: 2026LP03037) approved and issued by the National Medical Products Administration. The company's Jidesheng Snake Medicine Tablets application for clinical trials to add an indication for herpes zoster (liver-gallbladder damp-heat syndrome) has been approved. Jidesheng Snake Medicine Tablets is an existing marketed product of the company. This approval concerns the approval of a clinical trial application for adding an indication to a marketed traditional Chinese medicine product, and will not have a significant impact on the company's current operating performance.